News Column

Zhongyuan Confirmed Applying for Anti-cancer Vaccine Patent

August 6, 2014

BEIJING, August 6, SinoCast -- Zhongyuan Union Stem Cell Bioengineering's subsidiary is said to apply for a vaccine preparation patent that can enhance the ability of activating anti-tumor cells by 10,000 times and above.

Zhongyuan replied the subsidiary is indeed applying for the patent, but it is uncertain when the patent will be approved.

According to data by Chinese Tumor Biotherapy Association, there are 3.1 million cancer patients in China currently, annually newly-added patients numbered 2.2 million and annually deaths numbered 1.6 million, 1/4 of cancer deaths worldwide. Currently, it is urgent to research and develop anti-cancer drugs.

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Sinocast Health Care & Medicine Beat (China)

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters